Full Program

Media | Gallery | Contact

Home / 2024 SABCS® / Full Program

Tuesday, December 10
Wednesday, December 11
Thursday, December 12
Friday, December 13

Full Program

Tuesday, December 10

(All times are in CST)
12:00 – 1:30 pm	Prevention Special Session: Mechanisms of Obesity Related Risk for Breast Cancer and Approaches to Risk Reduction Moderator: Carol Fabian, University of Kansas Medical Center, Westwood, Kansas Lifestyle, Genetic, and Epigenetic Interactions in Predicting Development of Obesity and Response to Calorie Restriction and Physical Activity Speaker to be announced Achieving Sufficient Fat loss and Metabolic Improvement to Reduce Cancer Risk: Newer Generation GLP-1n and GIP Receptor Agonists (NUSH-Based Therapeutics) Robert Kushner, Northwestern University Feinberg School of Medicine, Chicago, Illinois Impact and Types of Exercise and Pharmacotherapy in Weight Loss John Jakicic, University of Kansas Medical Center, Westwood, Kansas Panel Discussion
12:00 – 1:45 pm	FDA Special Session: New Drug Approvals
12:00 – 1:45 pm	Special Session 3: Sex, Drugs, Rock and Roll Moderator: Christine Ambrosone, Roswell Park Comprehensive Cancer Center, Buffalo, New York Patient Advocate: Tomika Bryant Supplements and Cannabis Heather Greenlee, Fred Hutch Cancer Center, Seattle, Washington Sexual Health Don Dizon, Legorreta Cancer Center at Brown University/Lifespan Cancer Institute, Providence, Rhode Island Exercise During Treatment Rikki Cannioto, Roswell Park Comprehensive Cancer Center, Buffalo, New York Alcohol Marilyn Kwan, Kaiser Permanente Northern California, Pleasanton, California Panel Discussion
2:00 – 3:45 pm	Clinical Workshop: Dose Optimization in Breast Medical Oncology
2:00 – 3:45 pm	Translational Workshop: Cancer Immunology Discovery Approaches into Clinical Trials Moderator: Christine Desmedt, KU Leuven, Leuven, Belgium Multiplex Imaging for Precision Oncology Raza Ali, Cancer Research UK, Cambridge, United Kingdom Single Cell T-Cell Receptors and B-Cell Receptors Diether Lambrechts, Catholic University of Leuven, Leuven, Belgium Spatial Transcriptomics Christos Sotiriou, Institut Jules Bordet, Brussels, Belgium Cancer Immunology Discovery Approaches into Clinical Trials Emanuela Romano, Institut Curie, Paris, France Panel Discussion
4:00 – 4:30 pm	Review of Current Technologies
4:00 – 4:30 pm	Therapy Induced Evolution
4:00 – 4:30 pm	Neoadjuvant Management and Adaptive Strategies
4:00 – 5:30 pm	A Roadmap to Address the Global Health Disparities in Breast Cancer
4:00 – 5:45 pm	Educational Session 1: Mind the Gap—Breast Cancer in the Young Moderator: Matteo Lambertini, University of Genova - IRCCS Ospedale Policlinico San Martino, Genoa, Italy Patient Advocate: Na'Diah Smith Biology of Breast Cancer in Young Women Camila Dos Santos, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York Ovarian Suppression - Who, When, Why, and for How Long Prudence Francis, Peter MacCallum Cancer Centre, Melbourne, Australia Survivorship Jennifer Sheng, Johns Hopkins University, Baltimore, Maryland Panel Discussion
4:00 – 5:45 pm	Educational Session 2: Liquid Biopsy: MRD, CT DNA, and Monitoring Response to Treatment Moderator: Adrian Lee, University of Pittsburgh, Pittsburgh, Pennsylvania Patient Advocate: Ellen Landsberger Review of Current Technologies Heather Parsons, Dana-Farber Cancer Institute, Boston, Massachusetts Early Detection and Molecular Recurrent Disease Ben Park, Vanderbilt University Medical Center, Nashville, Tennessee Utility in the Metastatic Setting David Cescon, UHN Princess Margaret Cancer Centre, Toronto, Canada Panel Discussion
4:00 – 5:45 pm	Educational Session 3: Tumor Heterogeneity and Evolution Moderator: Reuben S. Harris, UT Health San Antonio, San Antonio, Texas Therapy Induced Evolution Nicholas Navin, UT MD Anderson Cancer Center, Houston, Texas Genomic and Microenvironment Determinants of Breast Cancer Progression Christina Curtis, Stanford University, Stanford, California Single Cell Genomics in Triple Negative Breast Cancer Panel Discussion Ashley Laughney, Weill Cornell Medicine, New York, New York Panel Discussion
4:00 – 5:45 pm	Educational Session 4: Optimizing Early HER2 Positive Breast Cancer Treatment Moderator: Javier Cortes, International Breast Cancer Center, Barcelona, Spain Neoadjuvant Management and Adaptive Strategies Gabe Sonke, Netherlands Cancer Institute, Amsterdam, Netherlands Treatment of Small Tumors in Early-Stage Setting Adrienne Waks, Dana-Farber Cancer Institute, Boston, Massachusetts Post Neoadjuvant Management for non pCR Joyce O'Shaughnessy, Baylor University, Dallas, Texas Panel Discussion
5:45 – 6:15 pm	Refreshment and Networking Break
6:15 – 7:00 pm	Late Breaking Oral Presentations

Wednesday, December 11

(All times are in CST)
7:00 – 8:30 am	Concurrent Poster Spotlight Sessions 1-5
8:30 – 9:00 am	Welcome and Opening Remarks
9:00 – 9:30 am	William L. McGuire Memorial Lecture
9:30 – 11:45 am	General Session 1
12:00 – 12:50 pm	Rapid Fire 1
12:00 – 2:00 pm	Poster Session 1
12:00 – 1:45 pm	Early Detection Moderator: Ismail Jatoi, UT Health San Antonio Mays Cancer Center, San Antonio, Texas Risk-Based Screening in the Average Population Karla Kerlikowske, University of California San Francisco, San Francisco, California Novel Imaging Modalities Connie Lehman, Harvard Medical School and Massachusetts General Hospital, Boston, Massachusetts Screening for High-Risk Women Speaker to be announced Panel Discussion
1:00 – 1:50 pm	Clinical Case Discussions
2:00 – 3:00 pm	State of the Art Session 1: The Winding Road of Immune Biomarkers in Early Breast Cancer Moderator: Sherene Loi, Peter MacCallum Cancer Centre, Melbourne, Australia TILs: An Update After 10 Years of Research Roberto Salgado, Peter MacCallum Cancer Centre, Melbourne, Australia Immune Biomarkers Beyond TILs Justin Balko, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee Deploying Immune Biomarkers in Clinical Trials Priyanka Sharma, University of Kansas Medical Center, Westwood, Kansas Panel Discussion
2:00 – 3:00 pm	Clinical Controversies Moderator: Monica Morrow, Memorial Sloan Kettering Cancer Center, New York, New York Omission of Axillary Staging in ER Positive Breast Cancer: Implications on Adjuvant Therapies Monica Morrow, Memorial Sloan Kettering Cancer Center, New York, New York Omission of Axillary Staging in ER+ Disease What is The Data? Elizabeth Mittendorf, Dana-Farber Cancer Institute, Boston, Massachusetts Omission of Axillary Staging in ER+ Disease Implications for Radiotherapy Speaker to be announced Omission of Axillary Staging in ER+ Disease: Implications for Adjuvant Systemic Therapy Kevin Kalinsky, Emory Winship Cancer Institute, Atlanta, Georgia Radiation Post pCR Richard Zellars, Indiana University School of Medicine, Indianapolis, Indiana Panel Discussion
4:00 – 5:45 pm	Educational Session 5: Unlocking New Targets with Molecular Degraders Moderator to be announced PROTACs Speaker to be announced Lysosome-targeting Chimeras Speaker to be announced Biparatropic Antibodies Speaker to be announced Panel Discussion
3:30 – 5:15 pm	Educational Session 6: Case Based Clinical Approach to ER Positive Metastatic Breast Cancer Moderator: Sarah Hurvitz, Fred Hutch Cancer Center, Seattle, Washington Patient Advocate: Amy Beumer PI3Kinase/AKT Pathway Targeting ESR1 Mutations CDK4/6 Resistance Genomics When to Rebiopsy: Tissue vs Liquid Biopsy Single Agent Hormonal Therapy Sonia Data Panel Discussion Michael Oliphant, Harvard Medical School, Boston, Massachusetts Aditya Bardia, UCLA David Geffen School of Medicine, Los Angeles, California Neil Vasan, Columbia University Irving Medical Center, New York, New York Dan Stover, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio
3:30 – 5:15 pm	Educational Session 7: The Best of AACR Speakers to be announced
3:30 – 5:15 pm	Educational Session 8: Optimizing Local Therapy Moderator: Tari King, Dana-Farber Brigham Cancer Center, Boston, Massachusetts Patient Advocate: Yvonne Florance Let’s Talk About PBI Atif Khan, Memorial Sloan Kettering Cancer Center, New York, New York Axillary Management: When to Dissect and When to Radiate Stephanie Wong, Jewish General Hospital Segal Cancer Centre, McGill University Medical School, Montreal, Canada Surgical Prevention and Management of Lymphedema Sarah McLaughlin, Mayo Clinic, Jacksonville, Florida Panel Discussion
5:30 – 7:00 pm	Poster Session 2

Thursday, December 12

(All times are in CST)
7:00 – 8:30 am	Concurrent Poster Spotlight Sessions 6-10
8:30 – 9:00 am	Plenary Lecture: Dissecting Disparities Speakers to be announced
9:00 – 11:45 am	General Session 2
12:00 – 2:00 pm	Poster Session 3
12:00 – 12:50 pm	Rapid Fire 2
12:30 – 1:45 pm	The Future of Cancer Genetics Is Here Patient Advocate: Tanja Spanic, Europa Donna Slovenia, Ljubljana, Slovenia Saturation Genome Editing-Based Functional and Clinical Classiﬁcation of VUS in BRCA2 Fergus Couch, Mayo Clinic, Rochester, Minnesota Updates on Risk Prediction Models Antonis Antoniou, Cancer Research UK Cambridge Center, Cambridge, United Kingdom Reversion Mutations in BRCA1/2 in Response to Therapy Katherine Nathanson, University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania Panel Discussion
1:00 – 1:50 pm	Molecular Tumor Board Jorge Reis-Filho, AstraZeneca, Gaithersburg, Maryland Dara Aisner, University of Colorado Anschutz Medical Campus, Aurora, Colorado Philippe Bedard, Princess Margaret Cancer Centre, Toronto, Canada Jenna Canzoniero, Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, Maryland Bob Riter, Cornell University, Ithaca, New York
2:00 – 3:00 pm	Translational Controversies Speakers to be announced How to Deﬁne Triple Negative Breast Cancer Rebecca Dent, National Cancer Center Singapore, Singapore Charles Perou, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina Tumor Agnostic Drug Development Funda Meric, MD Anderson Cancer Center, Houston, Texas Fabrice Andre, Institut Gustave Roussy, Villejuif, France
2:00 – 3:00 pm	State of the Art: Revolutionizing Diagnosis and Discovery with Artiﬁcial Intelligence Moderator: Fred Howard, University of Chicago, Chicago, Illinois Pathology Speaker to be announced Imaging and Screening Ritse Mann, Netherlands Cancer Institute, Amsterdam, Netherlands Drug Discovery, Deep Learning, and Large Data Management Speaker to be announced Panel Discussion
3:30 – 5:15 pm	Educational Session 9: Artiﬁcial Intelligence in the Clinic Moderator: Debra Patt, Texas Oncology-Austin Central, Austin, Texas Patient Advocate: Kay Firth-Butterfield Hazards and Opportunities Andrew Hantel, Dana-Faber Cancer Institute, Boston, Massachusetts Beyond Chat GPT: Generative AI in Healthcare Speaker to be announced Digital Tools for Clinical Practice Emily Ray, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina Panel Discussion
3:30 – 5:15 pm	Educational Session 10: Immunotherapy Moderator: Heather McArthur, UT Southwestern Medical Center, Dallas, Texas Immunotherapy in Early ER Positive Breast Cancer Cesar Santa Maria, John Hopkins Medicine, Baltimore, Maryland Optimization of Treatment in TNBC Marleen Kok, Netherlands Cancer Institute, Amsterdam, Netherlands The Future of Immunotherapy Evanthia Roussos Torres, University of Southern California, Los Angeles, California Panel Discussion
3:30 – 5:15 pm	Educational Session 11: Mind the Gap—Breast Cancer in Older Adults Moderator to be announced Patient Advocate: Sandi Stanford The Aging Immune System with Hormonal Changes Speaker to be announced Deﬁning and Avoiding Low Value Surgical Therapy Christina Minami, Brigham and Women's Hospital, New York, New York Systemic Therapies Hans Wildiers, University Hospital Leuven, Leuven, Belgium Panel Discussion
3:30 – 5:15 pm	Educational Session 12: The Biology and Treatment Implications of Organ Speciﬁc Metastases Moderator: Heide Ford, University of Colorado Denver School of Medicine, Denver, Colorado Patient Advocate: Christine Hodgdon, Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland Brain Metastases Diana Cittelly, University of Colorado Anschutz Medical Campus, Aurora, Colorado Liver Metastases Peter Vermeulen, GZA Hospital Sint-Augustinus, Antwerp, Belgium Bone Metastases Rachelle Johnson, Vanderbilt University Medical Center, Nashville Tennessee Panel Discussion
5:30 – 7:00 pm	Poster Session 4
8:00 PM – 10:30 pm	SABCS Celebration

Friday, December 13

(All times are in CST)
7:00 – 8:30 am	Concurrent Poster Spotlight Sessions 11-15
8:30 – 9:00 am	Plenary Lecture: Cell Atlases as Roadmaps in Cancer Immunology
9:00 – 11:45 am	General Session 3
12:00 – 2:00 pm	Poster Session 5
12:30 – 1:45 pm	New Directions in Breast Cancer Prevention Moderator: Gretchen Benson, National Cancer Institute, Bethesda, Maryland Prevention Vaccines: Where Are We Now and Where Are We Going? Olivera Finn, University of Pittsburgh, Pittsburgh, Pennsylvania Can We Use Biomarkers to Implement Prevention? Seema Khan, Feinberg School of Medicine of Northwestern University, Chicago, Illinois From Bench to Clinical Trial: A New Target for Breast Cancer Prevention Geoff Lindeman, Walter and Eliza Hall Institute of Medical Research, Parkville, Australia Panel Discussion
12:30 – 2:00 pm	The Pathologist's Conundrum: IHC testing in Breast Cancer
2:00 – 2:50 pm	Debate: All Patients Should be Oﬀered Universal Germline Genetic Testing Moderator: Virginia Kaklamani, UT Health San Antonio, San Antonio, Texas Opening Remarks and Polling Debate For Allison Kurian, Stanford University, Stanford, California Debate Against Raymond Kim, UHN Princess Margaret Cancer Centre, Toronto, Canada Closing Remarks and Polling
3:00 – 5:00 pm	Year in Review Moderators: Carlos Arteaga, UT Southwestern Medical Center, Dallas, Texas; and Virginia Kaklamani, UT Health San Antonio, San Antonio, Texas Translational Science Updates Pedram Razavi, Memorial Sloan Kettering Cancer Center, New York, New York Early Breast Cancer Updates Speaker to be announced Advanced Breast Cancer Updates Michael Danso, Virginia Oncology Associates, Norfolk, Virginia Basic Science Neil Vasan, Columbia University, New York, New York
5:00 – 5:30 pm	Reception Break
5:30 – 7:00 pm	View from the Trenches